In This Article:
Over the last 7 days, the United States market has risen by 2.4%, contributing to a remarkable 25% climb over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying small-cap stocks that are currently undervalued and exhibit insider activity can present intriguing opportunities for investors seeking potential growth.
Top 10 Undervalued Small Caps With Insider Buying In The United States
Name | PE | PS | Discount to Fair Value | Value Rating |
---|---|---|---|---|
OptimizeRx | NA | 1.1x | 44.15% | ★★★★★☆ |
Quanex Building Products | 33.3x | 0.9x | 38.67% | ★★★★☆☆ |
First United | 13.0x | 3.0x | 47.13% | ★★★★☆☆ |
Franklin Financial Services | 10.4x | 2.0x | 33.90% | ★★★★☆☆ |
McEwen Mining | 4.3x | 2.2x | 44.35% | ★★★★☆☆ |
Innovex International | 9.2x | 2.1x | 47.28% | ★★★★☆☆ |
ChromaDex | 305.2x | 4.9x | 29.74% | ★★★☆☆☆ |
ProPetro Holding | NA | 0.8x | 11.49% | ★★★☆☆☆ |
Delek US Holdings | NA | 0.1x | -75.07% | ★★★☆☆☆ |
Sabre | NA | 0.4x | -64.39% | ★★★☆☆☆ |
Let's explore several standout options from the results in the screener.
ChromaDex
Simply Wall St Value Rating: ★★★☆☆☆
Overview: ChromaDex is a bioscience company focused on developing and commercializing dietary supplements and ingredients, with a market cap of $0.19 billion.
Operations: ChromaDex's revenue is primarily derived from consumer products, followed by ingredients and analytical reference standards and services. The company's gross profit margin has shown an upward trend, reaching 61.45% in the latest period. Operating expenses are a significant cost component, with general and administrative expenses being the largest contributor.
PE: 305.2x
ChromaDex, a smaller player in the U.S. market, is gaining attention for its innovative health products like Niagen IV, now available nationwide. Despite a volatile share price recently, their financials show promise with Q3 2024 sales hitting US$25.58 million, up from US$19.5 million the previous year. Insider confidence is evident as individuals within the company have been purchasing shares over recent months, signaling potential growth optimism amidst projected revenue increases and expanding product lines.
-
Unlock comprehensive insights into our analysis of ChromaDex stock in this valuation report.
-
Gain insights into ChromaDex's historical performance by reviewing our past performance report.
SNDL
Simply Wall St Value Rating: ★★★☆☆☆
Overview: SNDL is a company engaged in liquor retail, cannabis retail, and cannabis operations with a market capitalization of CA$1.09 billion.
Operations: The company generates revenue primarily through liquor retail, cannabis retail, and cannabis operations. The gross profit margin has shown an upward trend, reaching 25.12% as of the latest reporting period.